4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing.
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.